Aug 15 |
Top Midday Gainers
|
Aug 15 |
Dow Surges Over 500 Points; US Retail Sales Rise In July
|
Aug 15 |
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
|
Aug 13 |
Cingulate GAAP EPS of -$5.47
|
Aug 13 |
Cingulate Reports Second Quarter 2024 Financial ResultsĀ and Provides Development Update on Major Milestones Achieved
|
Jul 15 |
Cingulate files for 6.6M common stock offering
|
Jun 28 |
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
|
Jun 25 |
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
|
Jun 25 |
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
|
May 8 |
Cingulate Reports First Quarter 2024 Financial ResultsĀ and Provides Clinical and Business Update
|